Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

AML1 interconnected pathways of leukemogenesis.

Joäelle Michaud1, Hamish S Scott, Robert Escher

  • 1Genetics and Bioinformatics Division, Walter and Eliza Hall Institute of Medical Research, Victoria, Australia.

Cancer Investigation
|March 20, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Automated reanalysis of genomic data for rare disease diagnostics at scale.

Nature medicine·2026
Same author

The germline landscape of pituitary adenomas: established and emerging predisposition genes.

The Journal of clinical endocrinology and metabolism·2026
Same author

[Slowly progressive, non-traumatic swelling of the left ankle. What does this have to do with rice grains?]

Praxis·2026
Same author

[Rapidly progressive neurocognitive symptoms - consider rare aetiologies].

Praxis·2026
Same author

Shaping the future of multiple myeloma with artificial intelligence and digital twins: from concept to clinic.

Frontiers in digital health·2026
Same author

Design and rationale of the EFFORTII project: a multicentric randomised-controlled trial on the impact of continued nutritional therapy at hospital discharge.

BMJ open·2026
Same journal

Profiling Immune-Related Adverse Events Associated with Imatinib: A Two-Decade Real-World Safety Study Based on FDA Adverse Event Reporting System.

Cancer investigation·2026
Same journal

Biomarker-Guided Adjuvant Therapy in Stage II/III Colon Cancer: A Systematic Review of Current Evidence and Clinical Implications.

Cancer investigation·2026
Same journal

Analysis of Second Primary Tumours in Cutaneous Lymphoma Populations.

Cancer investigation·2026
Same journal

The Heterogeneity of B Cells Potentially Contributes to Metastasis of Clear Cell Renal Cell Carcinomas.

Cancer investigation·2026
Same journal

The Association Between Lymphocyte-Monocyte Ratio, Tumor-Infiltrating Lymphocytes, and Tumor-Associated Macrophages with 3-Year Progression-Free Survival in Advanced Local Stage Nasopharyngeal Cancer Patients.

Cancer investigation·2026
Same journal

<i>In Vivo</i> Pharmacokinetics, Bio-Distribution and anti-Tumor Activity of Docetaxel-Loaded Folate Targeted Biocompatible Polymeric Micelles.

Cancer investigation·2026
See all related articles

The AML1 (Acute Myeloid Leukemia 1) transcription factor is crucial for blood cell development. Its alterations, through mutations or translocations, are implicated in leukemia, acting as both an oncogene and tumor suppressor.

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • The AML1 (Acute Myeloid Leukemia 1) transcription factor, also known as RUNX1, is frequently altered in leukemia via chromosomal translocations, polysomies, and point mutations.
  • AML1 is essential for the development of all hematopoietic lineages, and its functional level profoundly impacts hematopoiesis.
  • Dysregulation of AML1 impairs gene expression pathways critical for hematopoietic cell proliferation and differentiation.

Purpose of the Study:

  • To review the known AML1 target genes, interacting proteins, and gene alterations.
  • To discuss the effects of these alterations on AML1 function and its role in leukemia development.
  • To explore the interconnections within AML1-related signaling pathways for potential therapeutic strategies.

Main Methods:

Related Experiment Videos

  • Literature review of studies on AML1 gene alterations, target genes, and interacting proteins.
  • Analysis of the impact of these alterations on hematopoietic cell development and leukemia.
  • Discussion of AML1's dual role as an oncogene and tumor suppressor.

Main Results:

  • AML1 alterations are implicated in numerous acute leukemias through various pathogenic mechanisms.
  • Heterozygous AML1 mutations may require additional genetic events for leukemia development, influencing the leukemic phenotype.
  • AML1 is vital for regulating genes involved in hematopoietic cell development.

Conclusions:

  • AML1 plays a critical role in hematopoiesis, and its dysregulation is a key factor in leukemia pathogenesis.
  • Understanding AML1 interactions and signaling pathways is crucial for developing targeted leukemia therapies.
  • Further research into cumulative genetic events affecting AML1 function is needed to fully elucidate leukemia development.